| Title |
Publication Date |
Price |
Relevance |
Angiogenesis in Oncology
Drug Pipeline Update 2009
|
January 2009 |
£1285 |
48 % |
Vascular Targeting and Anti-angiogenesis in Oncology
Drug Pipeline Update 2007
|
January 2009 |
£1285 |
47 % |
Analytical Tool - Angiogenesis in Oncology
|
January 2009 |
£2660 |
47 % |
Analytical Tool - Competitive Outlook on Anti-Angiogenesis and Vascular Targeting in Oncology
|
January 2009 |
£2700 |
45 % |
Cardiovascular Molecular Imaging
|
July 2007 |
£130 |
35 % |
Cancer-Associated Thrombosis
|
August 2007 |
£115 |
31.5 % |
Drug Targets for Breast Cancer
|
January 2006 |
£1095 |
24.85 % |
Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology
|
October 2006 |
£1670 |
23.45 % |
Multi-Detector Computed Tomography in Oncology: Perfusion CT
|
August 2007 |
£125 |
22.4 % |
Preclinical Cancer Therapeutics 2007
Decoding Next Generation Drug Targets for Market Success
|
December 2006 |
£1600 |
22.4 % |
Textbook of Interventional Cardiovascular Pharmacology
|
April 2007 |
£140 |
22.05 % |
Triple Analysis: Apoptosis Agents, Protein Kinase Inhibitors and Anti-Angiogenic Agents in Oncology
|
December 2006 |
£4440 |
16.45 % |
Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents
|
October 2006 |
£2960 |
16.1 % |
Pipeline Insight: Molecular Targeted Cancer Therapies
More pipeline activity, less product differentiation
|
November 2008 |
£8000 |
15.75 % |
Prognostic and Predictive Factors in Gynecologic Cancers
|
September 2007 |
£55 |
15.05 % |
Melanoma - Targeted Therapeutics
|
July 2007 |
£1340 |
15.05 % |
Hypoxia-Inducible Factor (HIF)
Competitor Analysis
|
April 2009 |
£86 |
15 % |
Triple Progress Analysis: Melanoma, Colorectal & Lung Cancer
|
March 2006 |
£2960 |
12.95 % |
Targeted Therapies in Oncology
A World Review
|
December 2006 |
£4245 |
12.25 % |
Cancer Drug Resistance
2008
|
September 2008 |
£1675 |
11.55 % |
Global Pipeline Review & Analysis of Hematological Malignancies
|
March 2007 |
£2025 |
11.55 % |
Analytical Tool - Apoptosis in Oncology
|
January 2009 |
£2660 |
11.5 % |
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies
More drugs on the market, more targets in the pipeline
|
October 2006 |
£8000 |
11.2 % |
Breast Cancer Drug Discoveries
What the future holds
|
December 2008 |
£795 |
10.85 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1680 |
10.15 % |
Cardiovascular Drug Delivery
Technologies,Markets and Companies
|
May 2009 |
£1525 |
10.15 % |
Stakeholder Opinions: Primary Brain Cancer
Temozolomide Turns Heads
|
July 2007 |
£2005 |
9.45 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer
|
June 2007 |
£2365 |
9.1 % |
Antibody Drug Target Atlas in Oncology
|
June 2007 |
£1680 |
8.75 % |
Pipeline Insight: Molecular Targeted Cancer Therapies Can anything else revolutionize the market?
- Cancer
|
October 2007 |
£7600 |
8.5 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC
|
July 2007 |
£2365 |
8.4 % |
Nitric Oxide
Therapeutics, Markets and Companies
|
May 2009 |
£1710 |
8.4 % |
Market for Bioengineered Protein Drugs; The
|
January 2007 |
£2960 |
8.05 % |
Lpath, Inc. - Strategic Analysis Review
|
June 2009 |
£76 |
8 % |
Pipeline Insight: Non-Small Cell Lung Cancer
Pipeline set to offer only modest improvements
|
April 2008 |
£6000 |
7.7 % |
Pipeline Insight: Breast Cancer
Recent approvals increase pressure on pipeline candidates
|
April 2008 |
£6000 |
7.7 % |
Top 7 Cancer Indications
Therapeutic & Competitive Insights
|
January 2007 |
£5960 |
7.7 % |
ImClone Systems Incorporated - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
7.5 % |
EntreMed, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
7.5 % |
Rheumatoid Arthritis: Emerging drug discovery targets
And therapeutic candidates
|
October 2003 |
£375 |
7.5 % |
Molecular Imaging in Drug R&D and Medical Practice
Technologies, Applications, Markets
|
January 2008 |
£685 |
7.35 % |
Systems Biology
A Disruptive Technology
|
May 2008 |
£685 |
7.35 % |
Target Atlas in Oncology Drug Development: Targeted Therapies
|
March 2009 |
£3515 |
7 % |
Cordis Medical Device Company Intelligence Report
|
November 2007 |
£295 |
7 % |
Triple Target Atlas in Oncology Drug Development
|
March 2009 |
£2660 |
7 % |
Complete Target Atlas in Oncology Drug Development: From Tumor to Targeted Therapy
|
March 2009 |
£2660 |
7 % |
Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology
|
August 2006 |
£2960 |
6.65 % |
DePuy Medical Device Company Intelligence Report
|
December 2007 |
£295 |
6.65 % |
Cancer Therapeutics Markets
|
May 2008 |
£2075 |
6.65 % |
Takeda: Pipeline, Products, Performance, Potential
|
November 2007 |
£595 |
6.65 % |
Drug Delivery in Cancer
Technologies, Markets and Companies
|
May 2009 |
£1830 |
6.3 % |
Pipeline Insight: Hematological Malignancies Companies target niche indications to facilitate market entry
|
April 2009 |
£6000 |
5.95 % |
Stakeholder Opinions
Novel Therapeutic Approaches in Cardiovascular Medicine - Lack of Market Prospects for Biologics Expose An Opportunity for Cell and Gene Therapies
|
July 2008 |
£3800 |
5.95 % |
Cancer Biomarkers
Enhancing diagnostic, therapeutic and developmental strategies
|
May 2006 |
£2195 |
5.6 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas
|
June 2007 |
£2365 |
5.6 % |
Pipeline Insight: Cancer Overview
Increasing Diversity Offers Both High Risk And Reward
|
September 2007 |
£7600 |
5.6 % |
Breast Cancer Drug Pipeline Update 2009
|
January 2009 |
£1285 |
5.5 % |
Chemotherapy Market Insights, 2006-2016
A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
|
April 2006 |
£1900 |
5.25 % |
Commercial Insight Top 20 Cancer Therapeutics
|
July 2006 |
£8695 |
5.25 % |
RNAi
Technologies, Markets and Companies
|
May 2009 |
£1830 |
4.9 % |
The Executive Guide to Molecular Imaging
|
July 2007 |
£595 |
4.9 % |
Outlook for RNAi, 2007
siRNA and miRNA in biology, diagnostics and therapeutics
|
June 2007 |
£1495 |
4.55 % |
Immunotherapies and Vaccines for Cancer and Infectious Diseases
|
October 2008 |
£2290 |
4.55 % |
Cell Therapy
Technologies, Markets and Companies
|
May 2009 |
£2745 |
3.85 % |
Modern Biopharmaceuticals
Design, Development and Optimization, 4 Volumes
|
September 2005 |
£440 |
3.85 % |
Medical Nanotechnology Markets
|
September 2008 |
£2075 |
3.5 % |
Stakeholder Insight: Non-Small Cell Lung Cancer
The need for greater product differentiation in an increasingly crowded market
|
November 2006 |
£8000 |
3.15 % |
Cell Therapy Markets
|
July 2007 |
£2075 |
2.8 % |
